IDEA Collider: Innovation & Asymmetric Learning in Pharma

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer immunotherapy. As the industry prepares for the upcoming patent expiration of Merck's dominant checkpoint inhibitor Keytruda, companies are racing to claim the next oncology backbone. We analyze the three major strategies currently shaping the pipeline: Merck’s platform defense focusing on subcutaneous formulations and early-stage curative intent; the high-risk, high-reward displacement play of PD-1/VEGF bispecific inhibitors spearheaded by players like Akeso and Summit; and AstraZeneca’s tailored, tumor-specific approach combining immunotherapy with antibody-drug conjugates (ADCs) and targeted small molecules. The guests also dissect key clinical insights from the HARMONY-6 Phase 3 trials, the biological and tumor-localization benefits of dual-mechanism molecules over dual-drug cocktails, and the strategic importance of choosing between incremental portfolio expansion and blockbuster-seeking big bets. Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Alex Gray; LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/ Keep up with David Radwaner; LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/ Keep up with Tom Brockbank; LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30 years, MS therapies have primarily focused on controlling inflammation and visible relapses. Jason argues it’s time to look deeper and address the ongoing neurodegeneration driving long-term disability, known as Progression Independent of Relapse Activity (PIRA). We explore Immunic's investigational therapy, vidofludimus calcium, and its unique dual-mechanism approach: acting as a DHODH inhibitor for anti-inflammatory benefits while also activating the Nurr1 nuclear receptor to potentially provide direct neuroprotection. Jason shares insights from the EMPHASIS and CALIBER clinical trials, discusses why the industry needs safer immunomodulators rather than just broad immunosuppressants (especially as the MS population ages), and shares a fascinating biological link between MS remission during pregnancy and Nurr1 levels. Tune in to hear what the next 10 to 15 years hold for MS patients, including the ultimate goals of halting progression entirely and achieving remyelination. Episode Timestamps 00:00:00 - Introduction: Meet Jason Tardio, President and COO of Immunic. 00:02:01 - The Evolution of MS Treatment: Transitioning from purely anti-inflammatory approaches to addressing underlying neurodegeneration. 00:04:29 - What is PIRA?: Understanding Progression Independent of Relapse Activity and why patients still accumulate disability. 00:10:30 - The Dual-Mechanism Approach: How vidofludimus calcium combines DHODH inhibition with Nurr1 activation. 00:13:33 - The Power of Nurr1: Exploring the target's role in neuronal survival and the fascinating biological link to pregnancy in MS patients. 00:18:14 - Clinical Validation: Analyzing data from the EMPHASIS (relapsing MS) and CALIBER (progressive MS) trials. 00:27:42 - Standing Out in a Crowded Market: Why safety, tolerability, and avoiding broad immunosuppression matter, especially for aging MS patients facing immunosenescence. 00:36:08 - The Next 10 Years: Moving towards halting progression, potential remyelination, and the need to reclassify MS beyond relapsing and progressive labels. Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Jason Tardio; LinkedIn: https://www.linkedin.com/in/jason-tardio/ Keep up with Rick Ritacco: LinkedIn: https://www.linkedin.com/in/rritacco/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine. With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new FDA prioritizations and breakthrough clinical data. Athina shares insights from her meta-analysis on psilocybin and discusses the unique methodological challenges facing the industry, such as blinding integrity and the influence of expectancy effects in clinical trials. We explore the debate over whether the "psychedelic experience" is necessary for therapeutic benefit and how biotechs are balancing regulatory-friendly trial designs with patient safety. Finally, Athina looks toward the future of precision psychiatry, examining the role of biomarkers and the immense logistical challenges of scaling these intensive therapies within global healthcare systems. Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Athina Metaxa; LinkedIn: https://www.linkedin.com/in/athina-marina-metaxa/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts into relevant narratives. Sue discusses the unique challenges biotechs face with early positioning, explaining why teams often struggle with the paradox of having immediate scientific certainty about a molecule but immense clinical uncertainty about its future. We explore how to simplify scientific messaging without "dumbing it down," and Sue shares three proven strategies: reappropriating non-pharma nomenclature, evolving familiar drug classes, and focusing on tangible clinical outcomes. Sue also highlights the importance of cross-functional alignment, noting that a team's conviction to execute a narrative often matters more than having absolute precision. Tune in to hear her hilarious origin story involving the Boston Globe and oat bran donuts, and learn actionable advice on what biotechs should immediately remove from their websites. Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Sue Wood; LinkedIn: https://www.linkedin.com/in/susan-wood-266631244/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy. This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one. The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients. They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies. Episode Timestamps: 00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray. 00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints. 00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival. 00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead. 00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer. 00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies. 00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy. 00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Alex Gray; LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/ Keep up with David Radwaner; LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/ Keep up with Tom Brockbank; LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors. While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach. Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development. The conversation also highlights Anocca’s first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms. This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine. Episode Timestamps 00:00 – Introduction to TCR-T and solid tumor challenges 00:48 – Meet Reagan Jarvis and Anocca 02:05 – From New Zealand to Sweden: founder journey 03:08 – Frustration that sparked the platform 04:33 – Why CAR-T struggles in solid tumors 07:24 – The advantage of vertical integration in biotech 09:23 – First non-viral clinical trial challenges 10:56 – Umbrella trials in pancreatic cancer (KRAS focus) 14:13 – Biomarkers and building a target library 17:08 – Software, data, and machine learning in TCR discovery 18:08 – Regulatory pathways for individualized therapies 19:19 – Commercial landscape and target bottlenecks 22:29 – Expanding beyond oncology and partnerships 23:51 – Building a biotech company in Sweden 27:12 – Misconceptions about T-cell biology 30:04 – Milestones and 5-year vision 32:32 – Advice for scientific founders 34:17 – Closing thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Reagan Jarvis; LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/ Website: https://www.anocca.com/ Follow IDEA Pharma Website: https://www.ideapharma.com/ LinkedIn: https://www.linkedin.com/company/idea-pharma/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation. The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment. They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology. Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth. This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode Timestamps 00:00 – Introduction and Vir’s transformation story 00:40 – Marianne De Backer’s 30+ year pharma journey 02:42 – Vir’s origins and post-COVID strategic pivot 04:42 – Taking over as CEO during a crisis 06:33 – Lessons from the biotech downturn (“biotech winter”) 08:56 – Astellas partnership and T-cell engager strategy 09:52 – ProXtend platform: masked T-cell engagers explained 13:24 – Clinical data, safety, and tumor targeting 15:32 – Integrating new teams and scientific expertise 17:38 – Expanding the pipeline (HER2, EGFR, oncology) 19:50 – Hepatitis delta program and commercialization plans 22:11 – Funding strategy and biotech market outlook 25:37 – FDA interactions and regulatory perspective 28:13 – AI in drug discovery and clinical trials (Daisy platform) 31:34 – Culture: grit, ingenuity, collaboration, authenticity 34:21 – Personal reflections and leadership mindset 35:46 – Closing thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Marianne De Backer; LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/ Website: https://www.vir.bio/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ LinkedIn: https://www.linkedin.com/company/idea-pharma Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation. Episode Timestamps; 00:00 Welcome to Idea Collider 00:18 Kymera 2026 Catalysts 02:33 De Risking with Degraders 02:54 Targeted Protein Degradation 101 06:20 KT-621 STAT6 Degrader 08:16 Rethinking Type 2 Disease Treatment 12:21 Nello’s Path to CEO 16:32 Building a Standalone Biotech 23:19 Partnering with Big Pharma 26:51 Culture and Office Energy 32:03 Capital Plan and Potential Launches 36:24 Belief and Execution Mindset 39:00 Life Outside the Lab 40:07 Where to Follow Kymera 40:35 Closing Thanks Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Nello Mainolfi & Kymera LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/ Website: https://www.kymeratx.com/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ LinkedIn: https://www.linkedin.com/company/idea-pharma/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making. Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston, and Lucia Fernandez Barreiros, this conversation examines how cross-functional teams can interpret insights, manage uncertainty, and improve portfolio outcomes in complex drug development environments. The discussion covers artificial intelligence, asymmetric learning, forecasting challenges, strategic alignment, and the leadership mindset required to navigate innovation in biopharma. SAI MedPartners is a global consultancy that provides strategic insights, competitive intelligence, market research, and commercialization strategy to pharmaceutical, biotechnology, and medical device companies across the product lifecycle. This episode is a must-listen for leaders working across drug development, commercialization strategy, and pharmaceutical innovation. Keep up with the guests; Erik Nordhoy - President at SAI MedPartners LLC https://www.linkedin.com/in/erik-nordhoy-6996241/ John Barry - Executive Vice President at SAI MedPartners LLC https://www.linkedin.com/in/johnnbarry/ Matt Boucher, PhD - Director, Oncology BU, SAI MedPartners LLC https://www.linkedin.com/in/matthewbchr/ Jennifer Preston - VP, Artificial Intelligence Leader, SAI MedPartners LLC https://www.linkedin.com/in/jennifer-j-preston/ Lucia Fernandez Barreiros - Consulting Analyst, SAI MedPartners LLC https://www.linkedin.com/in/lucia-fernandez-barreiros-ba5260224/ Follow Mike Rea On; Website: https://ideacollider.simplecast.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider , host Mike Rea sits down with Michelle Werner , CEO of Alltrna , to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform. Episode Timestamps; 00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma 00:19 Meet Michelle Werner: Leading Alltrna’s tRNA Platform 02:09 From Cancer Clinic to Pharma: A Patient-First Career Path 06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style 09:37 Vulnerability & Psychological Safety: Building High-Trust Teams 11:46 A Personal Turning Point: Her Son’s Duchenne Diagnosis 17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation 18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna 22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions 28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines 33:49 From Preclinical to First-in-Human: Alltrna’s 2026 Milestones 36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease’s Inflection Point? Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options. This episode highlights a pivotal question for the industry: Are rare diseases at the same inflection point oncology experienced two decades ago? Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Michelle Werner; LinkedIn: https://www.linkedin.com/in/michelle-c-werner/ Website: https://www.alltrna.com/ Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project. Episode Timestamps; 00:00 Introduction and Welcome 00:27 Rick's Background and Project Overview 02:31 Client Team Introductions 05:32 Collaboration and Challenges 13:29 Defining the Mechanism and Market Positioning 23:52 Communication and Alignment 27:48 Navigating Internal and External Communication 33:15 Launch, Reflections, and Lessons Learned 41:14 Final Thoughts and Acknowledgements Keep up with the guests; Robyn Blackburn - Director Global Commercial Strategy CAR-T at Kite Pharma https://www.linkedin.com/in/robyn-blackburn-805b8b13/ Jayne Butler - Director of Strategic Initiatives at Fingerpaint Branding https://www.linkedin.com/in/jaynebutler/ Tracey Sacco - Former SVP Global Strategic Marketing at Acceleron https://www.linkedin.com/in/tracey-sacco-53 2a034/ Rick Ritacco - Head of Growth and Innovation https://www.linkedin.com/in/rritacco/ Follow Mike Rea On; Website: https://ideacollider.simplecast.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider , host Mike Rea speaks with Dr. Sekar Kathiresan , founder of Verve Therapeutics and now part of Eli Lilly , about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease . Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech founder, and now leader inside a global pharmaceutical company. The conversation explores how human genetics, CRISPR base editing, lipid nanoparticle delivery , and asymmetric learning converged to create a potential lifelong solution to cardiovascular disease. They also dive deep into the ethics of gene editing , global access and pricing, early intervention versus chronic care, FDA regulatory challenges, and what the Verve–Lilly acquisition means for the future of cardiometabolic medicine. This episode is a must-listen for anyone interested in biotech innovation, gene therapy, cardiovascular disease, and the future of preventive medicine . 00:00 Introduction and Guest Welcome 01:16 Sekar Kathiresan's Early Life and Education 03:19 Founding Verve and Transition to Entrepreneurship 05:35 The Science Behind Verve's Mission 10:27 Challenges and Breakthroughs in Gene Editing 20:05 Regulatory Hurdles and First Human Trials 25:11 Ethical Considerations in Gene Editing 27:06 Introduction to Drug Delivery and Ethical Considerations 27:51 Historical Context and Pioneers in Medical Procedures 28:35 Commercial and Ethical Challenges in Medicine 29:32 Innovations in Cardiovascular Treatments 32:49 The Role of Gene Editing in Long-term Health 37:55 Strategic Partnerships and Industry Insights 45:08 Reflections on the US Medical Ecosystem 48:54 Conclusion and Future Outlook Keep up with Sekar Kathiresan; LinkedIn: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/ Website: https://www.lilly.com/ Follow Mike Rea On; Website: https://ideacollider.simplecast.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows. The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation! 00:00 Welcome to Idea Collider 00:04 Introducing Alex Telford 01:59 Alex's Journey from UCL to Convoke Bio 05:29 The Mission and Work of Convoke Bio 07:57 Challenges in Pharma Decision Making 14:05 The Role of AI in Pharma 18:26 Knowledge Management and AI 27:58 Staying Updated in the Fast-Moving AI Field 30:25 AI's Impact on Industry Economics 31:38 AI in Clinical Trials and Drug Development 35:56 China's Role in Drug Discovery 39:24 Neuroscience and AI: Blurring the Lines 46:05 Future Predictions in Pharma 51:20 Addressing Cognitive Bias in Pharma 53:13 Concluding Thoughts and Future Directions Keep up with Alex Telford; LinkedIn: https://www.linkedin.com/in/alexander-telford/ Website: atelfo.github.io X: https://twitter.com/atelfo Substack: atelfo.substack.com Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome 00:25 Christian Rommel's Journey in Oncology 03:02 The Importance of Collaboration in Innovation 05:16 Balancing Risk and Reward in Drug Development 18:07 The Role of AI and Data in Modern R&D 22:33 Partnerships and External Learning 26:16 Balancing Legacy and Innovation in Biotech 27:18 Global Expansion and Leadership Diversity 27:27 Courage in Biotech Management 27:54 Inspiration from Roche Genentech 30:26 Commitment to Product Supply and Market Readiness 32:23 Challenges of Global Launches 35:53 Emerging Trends in Pharma: AI and Genetic Medicines 42:20 Decision-Making in Pharma 47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel; LinkedIn: https://www.linkedin.com/in/christian-rommel/ Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this insightful episode of IDEA Collider , Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies. 00:00 Introduction and Guest Background 00:56 Founding Thebans and Career Highlights 01:43 Leadership at Merck and J&J 02:18 Innovative Approaches at Parabilis Medicines 04:09 Defining and Tackling Undruggable Targets 09:27 Multivalent Drug Design and Bispecifics 13:53 AI and Data Science in Drug Development 19:28 Building and Leading World-Class Teams 25:41 The Importance of Holding Conviction as an Entrepreneur 26:25 Learning from Setbacks in the Biotech Industry 30:10 Challenges and Innovations in Drug Development 32:28 Navigating the Ups and Downs of the Biotech Industry 36:02 The Mission and Future of Parabilis 40:35 Personal Reflections and Advice for Entrepreneurs 46:46 Book Recommendations and Closing Thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Mathai Mammen; LinkedIn: https://www.linkedin.com/in/mathai-mammen/ Website: https://parabilismed.com/ Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider , host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel’s promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative. 00:00 Introduction and Guest Welcome 00:59 Early Career and Passion for Medicine 02:09 Transition to Industry and GSK Experience 04:50 Building Successful Organizations 07:42 Innovative Models in Pharma 19:03 Joining Candel Therapeutics and Vision for the Future 25:15 Transforming Cancer Treatment 27:24 Challenges in Biotech Market 28:45 Strategic Decisions and Prioritization 31:39 Collaborations and External Partnerships 33:07 Innovative Approaches and Future Prospects 44:23 Leadership and Personal Insights Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Paul Peter Tak; LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/ Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools. With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology. Chapter Summaries; 00:00 Introduction and Guest Welcome 00:27 Susan Galbraith's Career Journey 02:37 Defining Success in Oncology R&D 05:01 Early Phase Drug Development 07:09 Digital Health and Patient Experience 12:37 Global Collaboration and Innovation 15:05 AI and Future of Oncology 28:08 Diversity and Inclusion in Clinical Trials 33:46 Mentorship and Career Advice 37:45 Challenges and Future Outlook in Oncology 42:06 Closing Remarks and Call to Action Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Susan Gabraith; LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs. Join us as we explore John's journey from a first-generation American with Greek immigrant parents to a key figure in biomedicine. We'll discuss his education at the University of Chicago, his leadership role at Alnylam, drug delivery challenges for RNAi therapeutics, and the importance of strategic pharmaceutical alliances. John also shares his take on the current biotech environment, the impact of policy and regulation, and the promising future of genetic medicines and AI in drug discovery. Chapter Summaries; 00:00 Introduction to John Maraganore: Biotech Trailblazer 01:11 John's Early Life and Education 03:09 Joining Alnylam and the RNAi Revolution 04:56 Challenges and Successes at Alnylam 06:47 Current Biotech Funding Environment 08:17 Global Competition and US Leadership in Biotech 10:25 The Importance of In-Person Collaboration 12:01 Overcoming Drug Delivery Hurdles 15:21 Maintaining an Entrepreneurial Spirit in Biotech 17:00 Balancing Science and Business in Decision Making 20:27 Strategic Partnerships in Biotech 23:36 The Role of Biotech in Global Challenges 26:25 Advocating for Policy Changes in Biotech 30:41 Mentoring the Next Generation of Biotech Leaders 32:35 Future Frontiers in Biotech Innovation 36:08 John's Vision for the Future of Biomedicine 37:18 Communicating Innovation and Leadership Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with John Maraganore; LinkedIn: https://www.linkedin.com/in/john-maraganore/ Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

We are excited to tell you more about the IDEA Pharma and Exploristics partnership. IDEA’s COO, Jacqui Barendregt, asked Exploristics Founder and CEO Aiden Flynn five key questions about the innovative service model and, most importantly, the value to the pharmaceutical industry this newly formed partnership will bring.